医学检验服务
Search documents
兰卫医学:2024年报净利润-1.09亿 同比增长23.24%
Tong Hua Shun Cai Bao· 2025-04-27 08:54
Financial Performance - The company reported a basic earnings per share of -0.2700 yuan for 2024, an improvement of 22.86% compared to -0.3500 yuan in 2023 [1] - The net profit for 2024 was -1.09 billion yuan, showing a 23.24% improvement from -1.42 billion yuan in 2023 [1] - The return on equity (ROE) improved to -6.37% in 2024 from -7.35% in 2023, reflecting a 13.33% increase [1] - Operating revenue increased by 4.06% to 17.42 billion yuan in 2024 from 16.74 billion yuan in 2023 [1] - The net asset per share decreased by 6.97% to 4.14 yuan in 2024 from 4.45 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 21,074.79 million shares, accounting for 59.29% of the circulating shares, with an increase of 505.44 million shares compared to the previous period [1] - Shanghai Lanwei Investment Co., Ltd. remains the largest shareholder with 14,955.40 million shares, representing 42.08% of the total share capital [2] - Haian Group Co., Ltd. decreased its holdings by 797.04 million shares, now holding 1,528.71 million shares, which is 4.30% of the total [2] - New entrants among the top shareholders include Zeng Weixiong with 1,344.23 million shares (3.78%) and Shanghai Changsheng Tianhong Consulting Management Co., Ltd. with 797.04 million shares (2.24%) [2] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share, with a payout of 2 yuan (including tax) [2]